<DOC>
	<DOCNO>NCT00003930</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy surgery may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiation therapy plus combination chemotherapy treat patient stage II stage III bladder cancer remove surgery .</brief_summary>
	<brief_title>Radiation Therapy Combination Chemotherapy Treating Patients With Stage II Stage III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate safety tolerability induction chemoradiotherapy paclitaxel cisplatin follow selective bladder preservation radical cystectomy adjuvant chemotherapy patient stage II III muscle invasive carcinoma bladder previously treat transurethral tumor resection . - Evaluate efficacy transurethral tumor resection induction chemoradiotherapy achieve complete response patient population . - Assess value tumor parameter prognostic factor initial tumor response recurrence-free survival patient population . OUTLINE : Four six week prior transurethral resection , patient receive induction therapy comprise paclitaxel IV 1 hour day 1 , 8 , 15 , cisplatin IV 1 hour day 1 , 2 , 8 , 9 , 15 , 16 , radiotherapy twice daily day 1-5 , 8-12 , 17 . Four week induction therapy , patient undergo urologic evaluation . At 1-2 week evaluation , patient complete response receive consolidation therapy comprise paclitaxel IV 1 hour day 1 8 , cisplatin IV 1 hour day 1 , 2 , 8 , 9 , radiotherapy twice daily day 1-5 8-10 . Patients poor tumor response undergo cystectomy . At 12 week postconsolidation therapy 8 week post radical cystectomy , patient receive adjuvant chemotherapy comprise gemcitabine IV 30-60 minute follow cisplatin IV 1 hour every 3 week . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity . Patients follow every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 84 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II III ( T24a , Nx N0 , M0 ) primary carcinoma bladder muscle invasion Resectable disease Prostatic urethral involvement transitional cell carcinoma allow , completely resect evidence stromal invasion No tumorrelated hydronephrosis Positive lymph node must evaluate lymphadenectomy percutaneous needle biopsy No nodal metastases No distant metastases No 6 week since prior transurethral resection bladder tumor Functioning bladder PATIENT CHARACTERISTICS : Age : Adult Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL White blood cell ( WBC ) count least 4,000/mm^3 Absolute neutrophil count least 1,800/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Other : No prior concurrent malignancy within past 5 year except curatively treat nonmelanoma skin cancer , stage I prostate cancer , carcinoma situ cervix Not pregnant Negative pregnancy test Fertile patient must use effective contraception Medically operable PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy Surgery : See Disease Characteristics Other : No concurrent potential nephrotoxic ototoxic drug ( e.g. , aminoglycosides )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
</DOC>